Straits Times Index
3,333.75 +10.37 (+0.31%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,141.37 -88.82 (-0.49%) FTSE 100
8,243.40 +12.35 (+0.15%) Bitcoin USD
68,086.43 +524.64 (+0.78%) CMC Crypto 200
1,427.25 -1.32 (-0.09%)
REGN Aug 2024 965.000 put
| Previous close | 31.20 |
| Open | 31.20 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 965.00 |
| Expiry date | 2024-08-16 |
| Day's range | 31.20 - 31.20 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announ
- GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is Septe
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
